Opinion | The cancer vaccine interrupts a technology backlash The Washington PostCancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBCModerna's 177% Surge Burns Shorts in ‘Painful' $5.5 Billion Loss Bloomberg.comModerna's Shift to Cancer Company Lifts Stock Up 177% The New York Times
